ALSEN.PA Sensorion SA

Healthcare Biotechnology Euronext Paris
8.84 EUR
Close of Nov 7, 2026
5.25 40.40
Market cap
EUR 91.1M
P/E
-
P/B
1.12x
ROE
-101.5%
Dividend yield
-
Fundamental score
1.0/5

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.

Is ALSEN.PA undervalued?

Graham number

The Graham number of Sensorion SA cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Sensorion SA fundamental analysis

3 of 11 checks passed

ROE 0/2

The stock's ROE indicates a negative return (-70.61%) on shareholders' equity, suggesting poor financial performance.

ROA 0/2

The stock's ROA (-60.52%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

PBV 1/2

The stock's PBV ratio (1.93x) indicates a justifiable valuation, presenting a compelling choice for investors seeking reasonable returns.

DER 2/2

The stock has a minimal amount of debt (18%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

Revenue Growth 0/2

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

Net Profit Growth 0/2

This company's net profit has remained stagnant over the past five years, indicating a lack of growth and making it a less favorable investment option.

Assets Growth 0/2

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

Graham Number 1/1

The Graham number of this company suggests that its stock price may be undervalued, indicating a potentially attractive investment opportunity.

Dividend Growth 0/2

The company's dividend growth has remained unchanged for three years, signaling a lack of positive momentum and making it a less favorable investment choice.

Dividend 0/2

Investors should be cautious as the company hasn't distributed dividends in the last three years, possibly indicating financial challenges.

Buffet Intrinsic Value 0/1

The company's stock presents a potential concern as it appears overvalued (0) by Warren Buffett's formula, indicating that its market price exceeds its estimated intrinsic value.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Sensorion SA stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Sensorion SA

Sensorion SA, a biotechnology company, engages in the development of novel therapies to restore, treat, and prevent hearing loss disorders in France. The company develops SENS-501, a dual AAV vector gene therapy development product for restoring hearing in patients with mutations in OTOF gene in Phase 1/2 clinical trials; and SENS-601, a candidate for the treatment of hearing loss caused by mutations of the GJB2 gene in preclinical studies. It is also developing SENS-40, a s…

Full company profile